प्रोस्टेट कैंसर
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
कहाँ जाना है
इस ट्रायल के लिए भारत में 8 अस्पताल मरीज़ों को ले रहे हैं।
रजिस्ट्री समरी (तकनीकी)
Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called androgens) is reduced to very low levels. To reduce androgen levels in prostate cancer patients, androgen deprivation therapy (ADT) is often used. As androgens stimulate the growth of prostate cancer cells, low levels are needed to reduce or slow the growth of these tumors. In men …
Sponsor: Bayer
NCT05348876 on ClinicalTrials.gov
रजिस्ट्री में आखिरी बार 6 Jul 2026 को अपडेट किया गया · हमने 20 Oct 2026 को पढ़ा